Clinical trials: Gastroenteropancreatic
Gastroenteropancreatic Neuroendocrine Tumors
Community-based Neuroendocrine Tumor (NET) Research Study
The purpose of this trial is to assess time to disease progression of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors treated with Lanreotide Depot.
- Trial name
- NCT02730104
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Ipsen
Neuroendocrine Carcinoma
Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin
Cisplatin and Etoposide is the standard of care in NEC originating from the gastro-intestinal tract and lung, based on retrospective studies.
- Trial name
- NCT02687958
- Testing
- Everolimus
- Where
- 5 sites in Italy
- Volunteers
- 30 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Neuroendocrine Tumor G1 (NET G1)/Carcinoid, Neuroendocrine Tumor Grade 2
Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases
An international multi-centre, open, randomised, parallel-group phase II study comparing adjuvant treatment with 177Lu-DOTATATE to best supportive care in patients after complete surgical removal of neuroendocrine liver…
- Conditions
- Neuroendocrine Tumor G1 (NET G1)/Carcinoid, Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors, Liver Metastases
- Trial name
- NELMAS (NCT05987176)
- Testing
- Lutathera
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Imperial College London
Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System
Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs
The purpose of this study is to assess the safety and tolerability of pasireotide LAR in combination with everolimus in advanced metastatic gastroenteropancreatic or pulmonary neuroendocrine Tumors (NET).
- Trial name
- COOPERATE-1 (NCT01263353)
- Testing
- Pasireotide LAR followed by Pasireotide LAR + Everolimus, Everolimus followed by Pasireotide LAR + Everolimus
- Where
- 4 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Neoplasm
NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas
A pilot study to evaluate the anti-tumor efficacy of this novel combined regimen (NP-101 TQ Formula plus nivolumab and ipilimumab) in the second-line setting for EP-NECA.
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Neoplasm, Neuroendocrine Carcinoma, Mixed Neuroendocrine-Non Neuroendocrine Neoplasm
- Trial name
- NCT05262556
- Testing
- NP-101 (TQ Formula), Nivolumab (3mg/kg), Ipilimumab (1mg/kg)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Amr Mohamed MD
Symptomatic Refractory Resistant Carcinoid Disease
Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease
The purpose of this randomized, multicenter, Phase III study was to compare the efficacy of paseriotide LAR and octreotide LAR in patients whose disease-related symptoms are inadequately controlled by currently available…
- Trial name
- NCT00690430
- Testing
- Pasireotide, Octreotide
- Where
- 62 sites in United States, Argentina and 14 more
- Volunteers
- 186 people
- Sponsor
- Novartis Pharmaceuticals
Neuroendocrine Tumors
Identification of Biomarker Profiles GEP-NEN Patients
Although gastroenteropancreatic neuroendocrine neoplasia (GEP-NEN) were considered for years as rare tumors, their incidences are increasing.
- Trial name
- NCT02838862
- Where
- 3 sites in Germany
- Volunteers
- 470 people
- Sponsor
- University Hospital Schleswig-Holstein
Neuroendocrine Carcinoma
Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)
Neuroendocrine tumors of the lung include the small cell carcinoma (SCLC), and large cell neuroendocrine carcinoma (LCNEC) and represent 20% of lung cancer.
- Trial name
- NIPINEC (NCT03591731)
- Testing
- Nivolumab, Ipilimumab
- Where
- 7 sites in France
- Volunteers
- 185 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Neuroendocrine Neoplasm
Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors
This phase Ib trial is to find out the best dose, possible benefits and/or side effects of peposertib when given together with lutetium Lu 177 dotatate in treating patients with neuroendocrine tumors.
- Trial name
- NCT04750954
- Testing
- Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Gastroenteropancreatic Neuroendocrine Tumor
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
The study is being conducted to evaluate the efficacy, and safety of Lutetium (177Lu) Oxodotreotide Injection in subjects with advanced gastrointestinal pancreatic neuroendocrine tumors.
- Trial name
- NCT05884255
- Testing
- Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide, long-acting Octreotide
- Where
- 2 sites in China
- Volunteers
- 220 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Somatostatin Receptor-positive GEP-NET
A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea
This is a prospective, open-label, multi-center, non-comparative, non-interventional observational study to assess safety and effectiveness of Lutathera in patients with somatostatin receptor-positive GEP-NET in the real-world…
- Trial name
- NCT04946305
- Testing
- Lutathera
- Where
- 6 sites in South Korea
- Volunteers
- 89 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Cancer Not MSI-H or MMR-deficient, GIST
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
Assessment of the efficacy and safety of Regorafenib and Avelumab in patients with advanced or metastatic solid tumors (ten cohorts), once the Recommanded Phase II Dose (RP2D) has been determined (phase I trial).
- Conditions
- Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma, Biliary Tract Cancer
- Trial name
- REGOMUNE (NCT03475953)
- Testing
- Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib
- Where
- 7 sites in France
- Volunteers
- 747 people
- Sponsor
- Institut Bergonié
Neuroendocrine Tumors, Gastroenteropancreatic Neuroendocrine Tumor
Neuroendocrine Tumors - Patient Reported Outcomes
With so many therapeutic options available (i.e.: biologic therapy, liver directed therapy, radiotherapy and chemotherapy), the purpose of this project is to partner with patients on comparative effectiveness research (CER) to…
- Conditions
- Neuroendocrine Tumors, Gastroenteropancreatic Neuroendocrine Tumor, Lung Neuroendocrine Neoplasm, Neuroendocrine Carcinoma
- Trial name
- NET-PRO (NCT05064150)
- Where
- 14 sites in United States
- Volunteers
- 2,539 people
- Sponsor
- University of Iowa
Gastroenteropancreatic Neuroendocrine Tumours
Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours
Data from this study will contribute additional knowledge regarding patient outcomes and direct somatostatin analogue (SSA) treatment related costs in clinical practice in the Nordic countries.
- Trial name
- STREET (NCT02788565)
- Where
- 2 sites in Sweden
- Volunteers
- 156 people
- Sponsor
- Ipsen
Neuroendocrine Tumors, Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors
Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver
This study will look at whether it is practical and safe to give Lutathera directly into an artery of the liver (hepatic intraarterial infusion).
- Trial name
- NCT04544098
- Testing
- 177Lu-DOTATATE
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pheochromocytoma, Paraganglioma
211At-MABG in Adults With Advanced Neuroendocrine Cancers
Phase I dose escalation study of 211At-MABG in adults with advanced pheochromocytoma / paraganglioma (PPGL) or other NET-overexpressing cancers (as evidenced by positive MIBG imaging) who are refractory to, lacking, or ineligible…
- Conditions
- Pheochromocytoma, Paraganglioma, Neuroendocrine Tumors, Medullary Thyroid Cancer
- Trial name
- NCT07661420
- Testing
- 1 MBq/k of 211At-MABG Fractionated, 2 MBq/k1 of 211At-MABG Fractionated, 4 MBq/k of 211At-MABG Fractionated
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Pennsylvania
Advanced Solid Tumors, Glioblastoma
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
Prospective, open-label, dose-ranging, uncontrolled phase I/II study of Lurbinectedin in combination with irinotecan. The study will be divided into two stages: a Phase I dose escalation stage and a Phase II expansion stage.
- Conditions
- Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma (Excluding GIST), Endometrial Carcinoma
- Trial name
- NCT02611024
- Testing
- Lurbinectedin, Irinotecan
- Where
- 23 sites in United States, France and 4 more
- Volunteers
- 316 people
- Sponsor
- PharmaMar
Neuroendocrine Tumors, Gastroenteropancreatic Neuroendocrine Tumor
Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
The specific aim is of this study is to gain a better understanding of the patient characteristics, treatment responses, survival outcomes, and adverse events associated with PRRT in patients with gastroenteropancreatic primary…
- Trial name
- PRRT (NCT04090034)
- Testing
- Peptide Receptor Radionuclide Therapy
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Methodist Health System
Neuroendocrine Tumor, Gastroenteropancreatic
Surgical Intervention and the NETest
The purpose of this study is to evaluate the effect of different surgical resections (R0, R1, R2) on circulating NET transcripts (PCR score or NETest). A drop in circulating NET levels will be correlated with surgical excision.
- Trial name
- NETest_Sx (NCT03012789)
- Testing
- Surgery
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Wren Laboratories LLC
Gastro-Enteropancreatic Neuroendocrine Tumor
To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
The purpose of this clinical research is to confirm the optimal dose of 68Ga-satoreotide trizoxetan (68Ga-IPN01070), formerly 68Ga-OPS202, as a PET imaging agent to be used to detect and localize gastro-entero-pancreatic…
- Trial name
- NCT03220217
- Testing
- Satoreotide trizoxetan 5-20μg, Satoreotide trizoxetan 30-45μg
- Where
- 5 sites in United States, Austria and 1 more
- Volunteers
- 29 people
- Sponsor
- Ipsen